Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

NCT05448677 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Study terminated due to recruitement issues

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Ezurpimtrostat
DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

University Hospital, Grenoble

Collaborators

[object Object]